W. James Morris, Mira Keyes, Ingrid Spadinger, Winkle Kwan, Mitchell Liu, Michael McKenzie, Howard Pai, Tom Pickles and Scott Tyldesley Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancer Cancer 119
Version of Record online: 26 DEC 2012 | DOI: 10.1002/cncr.27911
In a population-based cohort of 1006 patients with low-risk and intermediate-risk prostate cancer, the actuarial disease-free survival (DFS) rates using competing risks (Fine and Gray) analysis after low-dose-rate brachytherapy are 96.7% at 5 years and 94.1% at 10 years using the standard Phoenix definition for biochemical recurrence. None of the traditional prognostic factors reaches statistical significance for DFS in univariate or multivariate analysis; however, among men who do not receive neoadjuvant and concomitant androgen-deprivation therapy (N = 348), increasing values for dose metrics predict improved DFS (P = .043).
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field